Colitis

Colitis is the inflammation of the large intestine, specifically the colon, which is a common cause of chronic or acute diarrhea in dogs and cats. The colon is responsible for water and electrolyte absorption, and the storage and propulsion of feces. Inflammation disrupts these functions, leading to clinical signs such as increased frequency of defecation, tenesmus, mucoid feces, and hematochezia. Colitis can be classified based on duration (acute vs. chronic), etiology (infectious, inflammatory, ischemic, neoplastic), and histopathologic pattern (lymphocytic-plasmacytic, eosinophilic, neutrophilic, granulomatous, etc.). In veterinary medicine, chronic colitis is often idiopathic and shares features with inflammatory bowel disease (IBD) in humans. The condition can be localized to the colon or part of a more diffuse gastrointestinal disorder.

The etiology of colitis is diverse and includes infectious agents, dietary factors, immune-mediated mechanisms, and neoplasia. Infectious causes include bacterial pathogens such as Salmonella spp., Campylobacter jejuni, Clostridium perfringens (especially type A with enterotoxin), Clostridium difficile, and Escherichia coli (particularly enteropathogenic and enterohemorrhagic strains). Viral causes include canine parvovirus (CPV-2) in dogs, feline panleukopenia virus (FPV) in cats, and coronaviruses. Parasitic causes include Trichuris vulpis (whipworm) in dogs, and Tritrichomonas foetus in cats, which is a common cause of chronic large-bowel diarrhea in young cats. Fungal causes are rare but include Histoplasma capsulatum and Prototheca spp. Non-infectious causes include dietary intolerance or allergy, adverse food reactions, and inflammatory bowel disease (IBD), which is an immune-mediated condition characterized by infiltration of the colonic mucosa with inflammatory cells. Other causes include antibiotic-associated colitis due to disruption of the normal microbiota, ischemic colitis secondary to vascular compromise, and neoplastic conditions such as lymphoma, adenocarcinoma, and leiomyosarcoma. In some cases, the cause remains unknown (idiopathic colitis).

Colitis is a common clinical problem in both dogs and cats. Acute colitis is frequently encountered in general practice, often due to dietary indiscretion or infectious agents. Chronic colitis is less common but represents a significant proportion of chronic diarrhea cases. In dogs, certain breeds may be predisposed to specific forms of colitis; for example, Boxers and French Bulldogs are predisposed to histiocytic ulcerative colitis, a severe form of IBD. German Shepherds may have an increased risk of IBD, including colitis. In cats, Tritrichomonas foetus infection is most common in young, purebred cats from catteries, with a median age of 1 year. There is no strong sex predilection for colitis. Geographic distribution varies with infectious agents; for example, histoplasmosis is more common in the Ohio and Mississippi River valleys. Seasonal patterns may be seen with certain infectious causes, such as parvovirus in puppies.

The pathophysiology of colitis involves disruption of the colonic mucosal barrier, leading to inflammation and altered fluid and electrolyte transport. The colonic epithelium is a single layer of columnar cells with tight junctions that regulate paracellular transport. In colitis, these tight junctions are disrupted, leading to increased permeability and leakage of fluid and solutes into the lumen. Inflammatory mediators, such as prostaglandins, leukotrienes, and cytokines, are released by activated immune cells (neutrophils, macrophages, lymphocytes, plasma cells) and contribute to mucosal damage and secretory diarrhea. In infectious colitis, pathogens may directly invade the epithelium (e.g., Salmonella, Campylobacter) or produce toxins that damage cells (e.g., Clostridium perfringens enterotoxin, Clostridium difficile toxins A and B). Parasitic infections like Trichuris vulpis cause mechanical damage and inflammation. In immune-mediated colitis, there is an inappropriate immune response to commensal bacteria or dietary antigens, leading to chronic inflammation. The inflammatory infiltrate can be predominantly lymphocytic-plasmacytic, eosinophilic, or neutrophilic, depending on the underlying cause. Chronic inflammation can lead to fibrosis, loss of goblet cells, and mucosal architectural distortion, resulting in persistent clinical signs. In severe cases, ulceration and hemorrhage occur, leading to hematochezia.

Predisposing factors for colitis include age (young animals are more susceptible to infectious causes, while older animals may have neoplastic causes), breed (Boxers and French Bulldogs for histiocytic ulcerative colitis, German Shepherds for IBD), diet (sudden dietary changes, ingestion of spoiled food, food allergies or intolerances), stress (which can alter the intestinal microbiome and immune function), concurrent diseases (e.g., exocrine pancreatic insufficiency, renal disease), immunosuppression (due to drugs or diseases), and antibiotic use (which can disrupt the normal colonic microbiota). Environmental factors such as overcrowding and poor sanitation increase the risk of infectious colitis. In cats, stress and cohabitation with other cats are risk factors for Tritrichomonas foetus infection.

Clinical signs of colitis are typically related to the large intestine and include increased frequency of defecation, tenesmus (straining to defecate), mucoid feces, hematochezia (fresh blood in stool), and urgency. Feces may be small in volume, and the animal may pass small amounts frequently. Some animals may have diarrhea, but it is often semi-formed or soft. Systemic signs such as vomiting, anorexia, and weight loss are less common in isolated colitis but may occur if the small intestine is also involved or if the colitis is severe. In acute colitis, signs may be sudden in onset and self-limiting. Chronic colitis is characterized by persistent or intermittent signs lasting more than 3 weeks. Physical examination may reveal mild abdominal discomfort, thickened bowel loops on palpation, and perianal irritation due to frequent defecation. In severe cases, dehydration and electrolyte imbalances may be present.

Differential diagnoses for colitis include: 1) Small intestinal diarrhea (e.g., inflammatory bowel disease, lymphoma, dietary intolerance) – key features: weight loss, vomiting, large volume diarrhea, but can coexist; 2) Parasitic infections (e.g., whipworms, Tritrichomonas foetus) – diagnosed by fecal flotation, PCR, or direct smear; 3) Bacterial infections (e.g., Salmonella, Campylobacter, Clostridium) – diagnosed by fecal culture or PCR; 4) Viral infections (e.g., parvovirus, coronavirus) – diagnosed by antigen testing or PCR; 5) Fungal infections (e.g., histoplasmosis) – diagnosed by cytology, histopathology, or antigen testing; 6) Neoplastic diseases (e.g., lymphoma, adenocarcinoma) – diagnosed by imaging, biopsy; 7) Antibiotic-associated colitis – history of antibiotic use; 8) Irritable bowel syndrome (IBS) – a functional disorder with no inflammatory changes; 9) Constipation or obstipation – history of infrequent defecation, hard feces; 10) Perianal disease (e.g., anal sac disease, perianal fistula) – may cause tenesmus and hematochezia. Definitive diagnosis requires a thorough diagnostic workup.

The diagnostic approach to colitis should be systematic. Step 1: Obtain a thorough history and perform a complete physical examination. Step 2: Fecal examination – direct smear, fecal flotation, and fecal culture/PCR for infectious agents (e.g., Salmonella, Campylobacter, Clostridium, Tritrichomonas). Step 3: Baseline laboratory tests – complete blood count (CBC), serum biochemistry profile, urinalysis, and possibly serum cobalamin and folate levels to assess small intestinal function. Step 4: Abdominal imaging – radiographs to rule out foreign bodies or obstruction, and abdominal ultrasound to assess bowel wall thickness and lymph nodes. Step 5: If chronic or severe, consider endoscopy with mucosal biopsies to obtain a histopathologic diagnosis. Step 6: In cases of suspected neoplasia, advanced imaging (CT, MRI) may be indicated. Step 7: If infectious causes are ruled out and biopsies show inflammatory changes, a diagnosis of inflammatory bowel disease (IBD) is made. Step 8: In refractory cases, consider additional testing such as fecal microbiome analysis or food trials.

Laboratory findings in colitis are often nonspecific. CBC may show mild neutrophilia or eosinophilia (especially in parasitic or eosinophilic colitis). Anemia may be present if there is significant blood loss. Serum biochemistry may reveal dehydration (elevated total protein, BUN, creatinine), electrolyte imbalances (hypokalemia, hyponatremia) due to diarrhea, and in severe cases, hypoalbuminemia if protein-losing enteropathy is present. Fecal examination may reveal parasitic ova (e.g., Trichuris eggs), trophozoites (e.g., Tritrichomonas on fresh smear), or bacterial overgrowth. Fecal culture and PCR can identify specific pathogens. In cats with Tritrichomonas, PCR on feces is the most sensitive test. Serum cobalamin and folate levels may be decreased if there is concurrent small intestinal disease. In cases of IBD, serum C-reactive protein (CRP) may be elevated, but it is not specific. Fecal calprotectin is a promising biomarker but is not widely available.

Abdominal radiographs are often unremarkable in colitis but may show gas-filled colon or fecal material. In cases of severe inflammation, a thickened colonic wall may be visible. Abdominal ultrasound is more sensitive and may reveal thickening of the colonic wall, loss of normal layering, and increased echogenicity of the mucosa. In chronic colitis, the wall may be diffusely thickened, and regional lymph nodes may be enlarged. Ultrasound can also help rule out intussusception or neoplasia. Endoscopy is the gold standard for evaluating the colonic mucosa. It allows direct visualization of the mucosa, which may appear erythematous, friable, ulcerated, or have a cobblestone appearance. Biopsies can be taken during endoscopy for histopathology. In cases of suspected neoplasia, CT or MRI may be useful for staging.

Cytology of colonic mucosal brushings or fine-needle aspirates of thickened bowel wall may reveal inflammatory cells (neutrophils, lymphocytes, plasma cells, eosinophils) or neoplastic cells. Histopathology of colonic biopsies is essential for definitive diagnosis. In acute colitis, there may be neutrophilic infiltration, mucosal edema, and epithelial necrosis. Chronic colitis often shows lymphocytic-plasmacytic infiltration, which is the most common form of IBD. Eosinophilic colitis is characterized by eosinophilic infiltration. Histiocytic ulcerative colitis, seen in Boxers, shows infiltration with PAS-positive macrophages. Granulomatous colitis may be seen with fungal infections. Special stains (e.g., Gram stain, GMS for fungi) can help identify infectious agents. Histopathology also assesses for architectural distortion, fibrosis, and goblet cell depletion.

Treatment of colitis depends on the underlying cause. For acute colitis, supportive care is often sufficient: dietary modification (bland diet, easily digestible fiber), fluid therapy if dehydrated, and possibly probiotics. If an infectious cause is identified, specific antimicrobial therapy is indicated. For example, metronidazole (10-15 mg/kg PO q12h) for Clostridium perfringens or Giardia, tylosin (10-20 mg/kg PO q12h) for bacterial diarrhea, and fenbendazole (50 mg/kg PO q24h for 3-5 days) for whipworms. For Tritrichomonas foetus in cats, ronidazole (30 mg/kg PO q24h for 14 days) is the drug of choice. For inflammatory bowel disease, treatment includes dietary management (novel protein or hydrolyzed diet), immunosuppressive drugs such as prednisolone (1-2 mg/kg PO q24h, then taper), and in refractory cases, additional immunosuppressants like chlorambucil (0.1-0.2 mg/kg PO q48h) or cyclosporine (5 mg/kg PO q24h). For histiocytic ulcerative colitis, enrofloxacin (5-10 mg/kg PO q24h) has been effective. In cases of severe hemorrhage or perforation, surgical intervention may be necessary. Supportive care includes antiemetics if vomiting, antidiarrheals (e.g., loperamide 0.1 mg/kg PO q8h) but caution with infectious causes, and probiotics (e.g., FortiFlora).

The prognosis for acute colitis is generally excellent with appropriate supportive care. Chronic colitis, particularly IBD, requires long-term management and may have a guarded prognosis depending on the severity and response to therapy. Histiocytic ulcerative colitis in Boxers can be difficult to manage but may respond to enrofloxacin. Neoplastic causes of colitis carry a poor prognosis, especially if metastatic. Overall, the prognosis is better for dogs and cats with colitis compared to small intestinal disease, as the colon has a greater regenerative capacity. Negative prognostic indicators include severe weight loss, hypoalbuminemia, and lack of response to immunosuppressive therapy.

Follow-up for colitis depends on the cause and severity. For acute colitis, re-evaluation in 2-3 days to ensure resolution of clinical signs. For chronic colitis, regular re-checks every 2-4 weeks initially to monitor response to therapy, then every 3-6 months for maintenance. Monitoring includes assessment of clinical signs, body weight, and serial laboratory tests (CBC, biochemistry, fecal exams). In cases of IBD, repeat endoscopy may be indicated if there is poor response or suspected neoplasia. For infectious colitis, repeat fecal testing to confirm clearance. For animals on immunosuppressive therapy, monitor for side effects (e.g., CBC, liver enzymes). Adjust drug dosages based on response and side effects.

Pearls: 1) Always perform a fecal examination before starting antibiotics, as many cases of acute colitis are self-limiting. 2) In cats with chronic large-bowel diarrhea, consider Tritrichomonas foetus, especially in young purebred cats. 3) In Boxers with colitis, consider histiocytic ulcerative colitis and treat with enrofloxacin. 4) Dietary management is crucial in IBD; use a novel protein or hydrolyzed diet. 5) Use metronidazole cautiously in cats due to neurotoxicity. Pitfalls: 1) Do not use antidiarrheals in cases of infectious colitis, as they may prolong the infection. 2) Avoid corticosteroids in infectious colitis. 3) Do not assume all chronic colitis is IBD; rule out infectious and neoplastic causes. 4) In cats, avoid using metronidazole at high doses for prolonged periods. 5) Do not forget to check for concurrent small intestinal disease, as it may affect treatment.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Metronidazole: 10-15 mg/kg PO q12h for 5-7 days for bacterial diarrhea or IBD (as an immunomodulator). 2) Tylosin: 10-20 mg/kg PO q12h for 7-14 days for bacterial diarrhea. 3) Fenbendazole: 50 mg/kg PO q24h for 3-5 days for whipworms. 4) Ronidazole: 30 mg/kg PO q24h for 14 days for Tritrichomonas foetus in cats. 5) Prednisolone: 1-2 mg/kg PO q24h for 2-4 weeks, then taper over 2-3 months for IBD. 6) Chlorambucil: 0.1-0.2 mg/kg PO q48h for cats with refractory IBD. 7) Cyclosporine: 5 mg/kg PO q24h for dogs and cats with IBD, monitor blood levels. 8) Enrofloxacin: 5-10 mg/kg PO q24h for histiocytic ulcerative colitis in dogs. 9) Sulfasalazine: 20-30 mg/kg PO q8h for dogs (not recommended in cats due to salicylate toxicity). 10) Mesalamine: 10-20 mg/kg PO q8h for dogs. 11) Probiotics: e.g., FortiFlora (1 packet PO q24h) for supportive care. 12) Fluid therapy: Lactated Ringer's solution or Normosol-R at maintenance (60-100 ml/kg/day IV) for dehydration. 13) Antiemetics: Maropitant (1 mg/kg SC q24h) if vomiting. 14) Antidiarrheals: Loperamide (0.1 mg/kg PO q8h) for non-infectious diarrhea, but avoid in infectious cases. 15) For severe IBD, consider budesonide (2 mg/m² PO q24h) for dogs. Always adjust dosages for renal or hepatic impairment and monitor for drug interactions.

Key studies and consensus guidelines: 1) The ACVIM consensus statement on the diagnosis and treatment of chronic inflammatory bowel disease in dogs and cats (2010) recommends a stepwise approach including dietary trials, antimicrobial therapy, and immunosuppressive drugs. 2) A study by Simpson et al. (2006) demonstrated that enrofloxacin is effective in treating histiocytic ulcerative colitis in Boxers. 3) A study by Gookin et al. (2006) established ronidazole as the treatment of choice for Tritrichomonas foetus in cats. 4) A meta-analysis by Allenspach et al. (2007) found that hypoalbuminemia and severe histologic lesions are negative prognostic indicators in canine IBD. 5) The ISCAID guidelines for the diagnosis and management of bacterial diarrhea in dogs and cats (2017) recommend fecal culture and PCR for diagnosis and targeted antimicrobial therapy. 6) A study by Jergens et al. (2010) showed that fecal calprotectin may be a useful biomarker for IBD in dogs. 7) The WSAVA guidelines for the diagnosis of gastrointestinal disease in dogs and cats (2010) emphasize the importance of histopathology for definitive diagnosis of IBD. 8) A study by Cerquetella et al. (2010) reviewed the role of probiotics in canine and feline colitis, suggesting potential benefits. 9) A study by Washabau et al. (2010) provided a comprehensive review of feline chronic diarrhea, including colitis. 10) The ACVIM consensus statement on the treatment of feline Tritrichomonas foetus infection (2016) recommends ronidazole as the first-line treatment.